I agree that this site is using cookies. You can find further informations here.
X
Aguggia, Marco
67  results:
Search for persons X
?
1

Assessing the Long-Term (48-Week) Effectiveness, Safety, an..:

Barbanti, Piero ; Egeo, Gabriella ; Proietti, Stefania...
Neurology and Therapy.  13 (2024)  3 - p. 611-624 , 2024
Link: https://doi.org/10.1007/..
 
?
2

Correction to: Assessing the Long-Term (48-Week) Effectiven..:

Barbanti, Piero ; Egeo, Gabriella ; Proietti, Stefania...
Neurology and Therapy.  , 2024
Link: https://doi.org/10.1007/..
 
?
3

Correction to: Ultra-late response (> 24 weeks) to anti-CGR..:

Barbanti, Piero ; Aurilia, Cinzia ; Egeo, Gabriella...
Journal of Neurology.  271 (2024)  5 - p. 2444-2445 , 2024
Link: https://doi.org/10.1007/..
 
?
4

Ultra-late response (> 24 weeks) to anti-CGRP monoclonal an..:

Barbanti, Piero ; Aurilia, Cinzia ; Egeo, Gabriella...
Journal of Neurology.  271 (2024)  5 - p. 2434-2443 , 2024
Link: https://doi.org/10.1007/..
 
?
5

Late Response to Anti-CGRP Monoclonal Antibodies in Migrain..:

Barbanti, Piero ; Aurilia, Cinzia ; Egeo, Gabriella...
Neurology.  101 (2023)  11 - p. 482-488 , 2023
Link: https://doi.org/10.1212/..
 
?
6

Early and sustained efficacy of fremanezumab over 24-weeks ..:

Barbanti, Piero ; Egeo, Gabriella ; Aurilia, Cinzia...
The Journal of Headache and Pain.  24 (2023)  1 - p. , 2023
Link: https://doi.org/10.1186/..
 
?
7

Conversion from chronic to episodic migraine in patients tr..:

Altamura, Claudia ; Brunelli, Nicoletta ; Marcosano, Marilena...
Journal of Neurology.  269 (2022)  11 - p. 5848-5857 , 2022
Link: https://doi.org/10.1007/..
 
?
8

Predictors of response to anti-CGRP monoclonal antibodies: ..:

Barbanti, Piero ; Egeo, Gabriella ; Aurilia, Cinzia...
The Journal of Headache and Pain.  23 (2022)  1 - p. , 2022
Link: https://doi.org/10.1186/..
 
?
9

Change in the second exteroceptive suppression period of th..:

Rota, Eugenia ; Aguggia, Marco ; Immovilli, Paolo...
Naunyn-Schmiedeberg's Archives of Pharmacology.  395 (2022)  5 - p. 607-611 , 2022
Link: https://doi.org/10.1007/..
 
?
10

The first report of the Italian Migraine Registry (I-GRAINE:

Barbanti, Piero ; Egeo, Gabriella ; Aurilia, Cinzia...
Neurological Sciences.  43 (2022)  9 - p. 5725-5728 , 2022
Link: https://doi.org/10.1007/..
 
?
11

Maintenance of response and predictive factors of 1‐year Ga..:

Vernieri, Fabrizio ; Brunelli, Nicoletta ; Marcosano, Marilena...
European Journal of Neurology.  30 (2022)  1 - p. 224-234 , 2022
Link: https://doi.org/10.1111/..
 
?
12

Long-term (>48 weeks) safety and tolerability of erenumab i..:

Aurilia, Cinzia ; Egeo, Gabriella ; Fofi, Luisa...
Journal of the Neurological Sciences.  429 (2021)  - p. 119287 , 2021
Link: https://doi.org/10.1016/..
 
?
13

Long term (48-weeks) effectiveness, safety and tolerability..:

Aurilia, Cinzia ; Cevoli, Sabina ; Egeo, Gabriella...
Journal of the Neurological Sciences.  429 (2021)  - p. 117716 , 2021
Link: https://doi.org/10.1016/..
 
?
14

Galcanezumab for the prevention of high frequency episodic ..:

for the GARLIT Study Group ; Vernieri, Fabrizio ; Altamura, Claudia...
The Journal of Headache and Pain.  22 (2021)  1 - p. , 2021
Link: https://doi.org/10.1186/..
 
?
15

Effectiveness, safety, and tolerability of galcanezumab in ..:

Vernieri, Fabrizio ; Altamura, Claudia ; Aurilia, Cinzia...
Neurological Sciences.  41 (2020)  S2 - p. 487-488 , 2020
Link: https://doi.org/10.1007/..
 
1-15